Fluoroquinolone-resistant tuberculosis: Implications in settings with weak healthcare systems

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 118-123

  Jabeen, Kauser ^a   Shakoor, Sadia ^a   Hasan, Rumina ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Drug resistant tuberculosis; Fluoroquinolone resistance; Health systems; Tuberculosis

Indexed keywords

QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COST OF ILLNESS; CROSS RESISTANCE; DRUG EXPOSURE; DRUG RESISTANT TUBERCULOSIS; FLUOROQUINOLONE RESISTANT TUBERCULOSIS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; DRUG EFFECTS; HEALTH CARE DELIVERY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DELIVERY OF HEALTH CARE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85001575056     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.01.006     Document Type: Article

References (96)

1. World Health Organization Global Tuberculosis Report 2014. WHO/HTM/TB/2014.08 2014, WHO, Geneva, Available at:, (accessed: November 10, 2014). http://www.who.int/tb/publications/global_report/en/.
2. Zumla A.I., Gillespie S.H., Hoelscher M., Philips P.P., Cole S.T., Abubakar I., et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014, 14:327-340.
3. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013, 13:1057-1098.
4. Gay J.D., DeYoung D.R., Roberts G.D. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother 1984, 26:94-96.
5. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
6. World Health Organization Treatment of tuberculosis guidelines. WHO/HTM/TB/2009.420. 2010, WHO, Geneva, Available at:, (accessed: December 28, 2014). http://www.who.int/tb/publications/2010/9789241547833/en/, 4th edition.
7. World Health Organization Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014. 11 2014, WHO, Geneva, Available at:, (accessed: December 28, 2014). http://www.who.int/tb/publications/pmdt_companionhandbook/en/.
8. Ziganshina L.E., Titarenko A.F., Davies G.R. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013, 6:CD004795.
9. Yew W.W., Kwan S.Y., Ma W.K., Khin M.A., Chau P.Y. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990, 26:227-236.
10. Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007, 51:576-582.
11. Yew W.W., Chan C.K., Leung C.C., Chau C.H., Tam C.M., Wong P.C., et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003, 124:1476-1481.
12. Ziganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008, (1). CD004795; 1-59.
13. Hawkey P.M. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003, 51(Suppl 1):29-35.
14. Malik S., Willby M., Sikes D., Tsodikov O.V., Posey J.E. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012, 7(6):e39754.
15. Noor R., Akhter S., Rahman F., Munshi S.K., Kamal S.M., Feroz F. Frequency of extensively drug-resistant tuberculosis (XDR-TB) among re-treatment cases in NIDCH, Dhaka, Bangladesh. J Infect Chemother 2013, 19:243-248.
16. Lourenco M.C., Junior I.N., De Souza M.V. In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil. Med Mal Infect 2007, 37:295-296.
17. Hu Y., Mathema B., Wang W., Kreiswirth B., Jiang W., Xu B. Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China. Tuberculosis (Edinb) 2011, 91:238-243.
18. Zhao Y., Xu S., Wang L., Chin D.P., Wang S., Jiang G., et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
19. Li X., Wang H., Jing H., Wang Y., Yu C., Wang J., et al. Population-based surveillance of extensively drug-resistant tuberculosis in Shandong Province, China. Int J Tuberc Lung Dis 2012, 16:612-614.
20. Liu Q., Zhu L., Shao Y., Song H., Li G., Zhou Y., et al. Rates and risk factors for drug resistance tuberculosis in northeastern China. BMC Public Health 2013, 13:1171.
21. Tessema B., Beer J., Emmrich F., Sack U., Rodloff A.C. First- and second-line anti-tuberculosis drug resistance in northwest Ethiopia. Int J Tuberc Lung Dis 2012, 16:805-811.
22. Paramasivan C.N., Rehman F., Wares F., Sundar Mohan N., Sundar S., Devi S., et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 2010, 14:243-246.
23. Verma J.S., Nair D., Rawat D., Manzoor N. Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis. Indian J Med Microbiol 2011, 29:280-282.
24. Jain A., Dixit P., Prasad R. Pre-XDR and XDR in MDR and ofloxacin and kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis (Edinb) 2012, 92:404-406.
25. Salvo F., Dorjee K., Dierberg K., Cronin W., Sadutshang T.D., Migliori G.B., et al. Survey of tuberculosis drug resistance among Tibetan refugees in India. Int J Tuberc Lung Dis 2014, 18:655-662.
26. Kelly P.M., Ardian M., Waramori G., Anstey N.M., Syahrial H., Tjitra E., et al. A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia. Int J Tuberc Lung Dis 2006, 10:167-171.
27. Rao N.A., Irfan M., Soomro M.M., Mehfooz Z. Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. J Coll Physicians Surg Pak 2010, 20:262-265.
28. Jabeen K., Shakoor S., Chishti S., Ayaz A., Hasan R. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005-2009. Emerg Infect Dis 2011, 17:564-566.
29. Rafiq Y., Jabeen K., Hasan R., Jafri S., Laiq R., Malik F., et al. Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi, Pakistan: data from community-based field clinics. Antimicrob Agents Chemother 2011, 55:929-930.
30. Gler M.T., Guilatco R.S., Guray C.V., Tupasi T.E. Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Int J Tuberc Lung Dis 2012, 16:1326-1330.
31. Dalton T., Cegielski P., Akksilp S., Asencios L., Campos Caoili J., Cho S.N., et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
32. Punga V.V., Jakubowiak W.M., Danilova I.D., Somova T.R., Volchenkov G.V., Kazionnyy B.Y., et al. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis 2009, 13:1309-1312.
33. Toungoussova O.S., Mariandyshev A.O., Bjune G., Caugant D.A., Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis 2005, 24:202-206.
34. Seddon J.A., Hesseling A.C., Marais B.J., Jordaan A., Victor T., Schaaf H.S. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012, 16:928-933.
35. Schaaf H.S., Hesseling A.C., Rautenbach C., Seddon J.A. Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?. Int J Tuberc Lung Dis 2014, 18:770-773.
36. Chaiprasert A., Srimuang S., Tingtoy N., Makhao N., Sirirudeeporn P., Tomnongdee N., et al. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update. Int J Tuberc Lung Dis 2014, 18:961-963.
37. Prammananan T., Chaiprasert A. Leechawengwongs M. 8-years experience of fluoroquinolone susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. Int J Antimicrob Agents 2011, 37:84-85.
38. Temple B., Ayakaka I., Ogwang S., Nabanjja H., Kayes S., Nakubulwa S., et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008, 47:1126-1134.
39. van den Boogaard J., Semvua H.H., van Ingen J., Mwaigwisya S., van der Laan T., van Soolingen D., et al. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J Antimicrob Chemother 2011, 66:1810-1814.
40. Migliori G.B., Langendam M.W., D'Ambrosio L., Centis R., Blasi F., Huitric E., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012, 40:814-822.
41. van der Starre W.E., van Nieuwkoop C., Paltansing S., van't Wout J.W., Groeneveld G.H., Becker M.J., et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011, 66:650-656.
42. Gallini A., Degris E., Desplas M., Bourrel R., Archambaud M., Montastruc J.L., et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010, 65:2650-2657.
43. Adam H.J., Hoban D.J., Gin A.S., Zhanel G.G. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009, 34:82-85.
44. Hsu D.I., Okamoto M.P., Murthy R., Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005, 55:535-541.
45. Long R., Chong H., Hoeppner V., Shanmuganathan H., Kowalewska-Grochowska K., Shandro C., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
46. Shen G.H., Tsao T.C., Kao S.J., Lee J.J., Chen Y.H., Hsieh W.C., et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012, 39:201-205.
47. Goyet S., Vlieghe E., Lim K., van Griensven J., Borand L., Thong P., et al. Fluoroquinolone resistance and Mycobacterium tuberculosis: CAP guidelines play an important role. Int J Tuberc Lung Dis 2014, 18:628-630.
48. Grossman R.F., Hsueh P.R., Gillespie S.H., Blasi F. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 2014, 18:14-21.
49. Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370.
50. van der Heijden Y.F., Maruri F., Blackman A., Mitchel E., Bian A., Shintani A.K., et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents 2013, 42:232-237.
51. Yew W.W., Chan C.K., Chau C.H., Tam C.M., Leung C.C., Wong P.C., et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000, 117:744-751.
52. Ho J., Jelfs P., Sintchenko V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 2014, 26:149-153.
53. Cegielski J.P., Dalton T., Yagui M., Wattanaamornkiet W., Volchenkov G.V., Via L.E., et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014, 59:1049-1063.
54. Huang T.S., Kunin C.M., Shin-Jung Lee S., Chen Y.S., Tu H.Z., Liu Y.C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
55. Park I.N., Hong S.B., Oh Y.M., Lim C.M., Lee S.D., Lew W.J., et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007, 11:319-324.
56. Daley C.L., Horsburgh C.R. Editorial commentary: Treatment for multidrug-resistant tuberculosis: it's worse than we thought!. Clin Infect Dis 2014, 59:1064-1065.
57. Chien J.Y., Lai C.C., Tan C.K., Yu C.J., Hsueh P.R. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan. Clin Infect Dis 2013, 56:1054-1055.
58. Falzon D., Gandhi N., Migliori G.B., Sotgiu G., Cox H.S., Holtz T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168.
59. Migliori G.B., Lange C., Girardi E., Centis R., Besozzi G., Kliiman K., et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. Eur Respir J 2008, 31:904-905.
60. Kurbatova E.V., Gammino V.M., Bayona J., Becerra M.C., Danilovitz M., Falzon D., et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012, 16:1335-1343.
61. Basit A., Ahmad N., Khan A.H., Javaid A., Syed Sulaiman S.A., Afridi A.K., et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One 2014, 9:e93206.
62. Johnston J.C., Shahidi N.C., Sadatsafavi M., Fitzgerald J.M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
63. Bastos M.L., Hussain H., Weyer K., Garcia-Garcia L., Leimane V., Leung C.C., et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014, 59:1364-1374.
64. Takiff H., Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 2011, 55:5421-5429.
65. Jindani A., Harrison T.S., Nunn A.J., Phillips P.P., Churchyard G.J., Charalambous S., et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
66. Merle C.S., Fielding K., Sow O.B., Gninafon M., Lo M.B., Mthiyane T., et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014, 371:1588-1598.
67. Gillespie S.H., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S.R., et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
68. Lalloo U.G. Short-course Bangladesh regimen for multidrug-resistant tuberculosis: a step in the right direction?. Int J Tuberc Lung Dis 2014, 18:1137-1138.
69. Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-692.
70. Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014, 18:1188-1194.
71. Aung K.J., Van Deun A., Declercq E., Sarker M.R., Das P.K., Hossain M.A., et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014, 18:1180-1187.
72. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2011.6 2011, WHO, Geneva, Available at:, (accessed: November 10, 2014). http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.
73. Jiang R.H., Xu H.B., Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents 2013, 42:36-41.
74. Koh W.J., Lee S.H., Kang Y.A., Lee C.H., Choi J.C., Lee J.H., et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013, 188:858-864.
75. Jo K.W., Lee S.D., Kim W.S., Kim D.S., Shim T.S. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2014, 18:39-43.
76. Ajbani K., Nikam C., Shetty A., Soman R., Rodrigues C. Multidrug-resistant tuberculosis with fluoroquinolone resistance: sinister association with other drugs and ominous implications for treatment. Clin Infect Dis 2014, 59:138-139.
77. Pasipanodya J.G., Gumbo T. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 2011, 11:457-463.
78. Laxminarayan R., Heymann D.L. Challenges of drug resistance in the developing world. BMJ 2012, 344:e1567.
79. Wells W.A., Ge C.F., Patel N., Oh T., Gardiner E., Kimerling M.E. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One 2011, 6:e18964.
80. Glass B.D. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med 2014, 5:11-22.
81. Okeke I.N., Lamikanra A., Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999, 5:18-27.
82. Shakoor O., Taylor R.B., Behrens R.H. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997, 2:839-845.
83. Bhargava A., Kalantri S.P. The crisis in access to essential medicines in India: key issues which call for action. Indian J Med Ethics 2013, 10:86-95.
84. Leung E., Weil D.E., Raviglione M., Nakatani H. The WHO policy package to combat antimicrobial resistance. Bull World Health Organ 2011, 89:390-392.
85. Shin S.S., Keshavjee S., Gelmanova I.Y., Atwood S., Franke M.F., Mishustin S.P., et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010, 182:426-432.
86. Spence D.P., Hotchkiss J., Williams C.S., Davies P.D. Tuberculosis and poverty. BMJ 1993, 307:759-761.
87. Abdulah R. Antibiotic abuse in developing countries. Pharmaceut Reg Affairs 2012, 1. 1000e106.
88. Love D.C., Davis M.F., Bassett A., Gunther A., Nachman K.E. Dose imprecision and resistance: free-choice medicated feeds in industrial food animal production in the United States. Environ Health Perspect 2010, 119:279-283.
89. Cabello F.C. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol 2006, 8:1137-1144.
90. Wei R., Ge F., Huang S., Chen M., Wang R. Occurrence of veterinary antibiotics in animal wastewater and surface water around farms in Jiangsu Province. China. Chemosphere 2011, 82:1408-1414.
91. Companyo R., Granados M., Guiteras J., Prat M.D. Antibiotics in food: legislation and validation of analytical methodologies. Anal Bioanal Chem 2009, 395:877-891.
92. Marshall B.M., Levy S.B. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev 2011, 24:718-733.
93. Pulla P. Doctors' leaders in India call for ban on prophylactic antibiotics in poultry. BMJ 2014, 349:g5052.
94. Murray C.J., Frenk J. A framework for assessing the performance of health systems. Bull World Health Organ 2000, 78:717-731.
95. Van Boeckel T.P., Gandra S., Ashok A., Caudron Q., Grenfell B.T., Levin S.A., et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014, 14:742-750.
96. Rabinowitz P.M., Kock R., Kachani M., Kunkel R., Thomas J., Gilbert J., et al. Toward proof of concept of a one health approach to disease prediction and control. Emerg Infect Dis 2013, 19(12):e130265.